Rapid spread and genetic diversification of HIV type 1 subtype C in a rural area of southern Mozambique

AIDS Research and Human Retroviruses

Volumn 24, Issue 2, 2008, Pages 327-335

  Lahuerta, Maria ^a   Aparicio, Ester ^b   Bardaji, Azucena ^a,c   Marco, Sandra ^b   Sacarlal, Jahit ^c,d   Mandomando, Inacio ^c   Alonso, Pedro ^a,c   Martinez, Miguel Angel ^b   Menendez, Clara ^a,c   Naniche, Denise ^a,e  

^a CENTRE FOR RESEARCH IN ENVIRONMENTAL EPIDEMIOLOGY CREAL   (Spain)

^b HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^c Ministérioda Saúde   (Mozambique)

^d EDUARDO MONDLANE UNIVERSITY   (Mozambique)

^e HOSPITAL CLÍNIC   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CONTROLLED STUDY; FEMALE; GENETIC DISTANCE; GENETIC VARIABILITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; LONG TERMINAL REPEAT; MAJOR CLINICAL STUDY; NONHUMAN; NUCLEOTIDE SEQUENCE; PHYLOGENY; PRIORITY JOURNAL; UNINDEXED SEQUENCE;

ADOLESCENT; ADULT; CLUSTER ANALYSIS; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; FEMALE; GENOTYPE; HIV INFECTIONS; HIV LONG TERMINAL REPEAT; HIV PROTEASE; HIV-1; HUMANS; MIDDLE AGED; MOLECULAR SEQUENCE DATA; MOZAMBIQUE; PHYLOGENY; PREGNANCY; RURAL POPULATION; SEQUENCE ANALYSIS, DNA; SEQUENCE HOMOLOGY; VARIATION (GENETICS);

EID: 39549093532     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2007.0134     Document Type: Article

References (46)

1. UNAIDS/WHO: AIDS Epidemic Update: December 2006. UNAIDS/WHO, Geneva, 2006.
2. Leitner T, Korber B, Daniels M, Calef C, et al.: HIV-1 subtype and circulating recombinant form (CRF) reference sequences, 2005. Sequence Compendium. http://www.hiv.lanl.gov/content/hiv-db/REVIEWS/reviews.html. Los Alamos National Laboratories, Los Alamos, NM, 2005.
3. Julg B and Goebel FD: HIV genetic diversity: Any implications for drug resistance? Infection 2005;33:299-301.
4. Butler IF, Pandrea I, Marx PA, and Apetrei C: HIV genetic diversity: Biological and public health consequences. Curr HIV Res 2007;5:23-45.
5. Thomson MM and Najera R: Molecular epidemiology of HIV-1 variants in the global AIDS pandemic: An update. AIDS Rev 2005;7:210-224.
6. Geretti AM: HIV-1 subtypes: Epidemiology and significance for HIV management. Curr Opin Infect Dis 2006;19:1-7.
7. Geretti AM: Clinical implications of HIV drug resistance to nucleoside and nucleotide reverse transcriptase inhibitors. AIDS Rev 2006;8:210-220.
8. Kantor R and Katzenstein D: Polymorphism in HIV-1 non-subtype B protease and reverse transcriptase and its potential impact on drug susceptibility and drug resistance evolution. AIDS Rev 2003;5:25-35.
9. Montes B, et al.: Comparison of drug resistance mutations and their interpretation in patients infected with non-B HIV-1 variants and matched patients infected with HIV-1 subtype B. J Acquir Immune Defic Syndr 2004;35:329-336.
10. Vergne L, et al.: Genetic diversity of protease and reverse transcriptase sequences in non-subtype-B human immunodeficiency virus type 1 strains: Evidence of many minor drug resistance mutations in treatment-naive patients. J Clin Microbiol 2000;38:3919-3925.
11. Vergne L, et al.: Natural polymorphism in protease and reverse transcriptase genes and in vitro antiretroviral drug susceptibilities of non-B HIV-1 strains from treatment-naive patients. J Clin Virol 2006;36:43-49.
12. Perno CF, et al.: Minor mutations in HIV protease at baseline and appearance of primary mutation 90M in patients for whom their first protease-inhibitor antiretroviral regimens failed. J Infect Dis 2004;189:1983-1987.
13. UNAIDS/WHO. Uniting the world against AIDS. http://www.unaids.org/en/ Regions_Countries/Countries/mozambique.asp. UN Technical Working Group, Mozambique, 2006.
14. Bellocchi MC, et al.: Subtype analysis and mutations to antiviral drugs in HIV-1-infected patients from Mozambique before initiation of antiretroviral therapy: Results from the DREAM programme. J Med Virol 2005;76:452-458.
15. Parreira R, et al.: Genetic characterization of human immunodeficiency virus type 1 from Beira, Mozambique. Microbes Infect 2006;8:2442-2451.
16. Menendez C, et al.: Prevalence and risk factors of sexually transmitted infections and cervical neoplasia in women from a rural area of Southern Mozambique (submitted for publication).
17. Menendez C, et al.: Combination of interventions for malaria prevention in pregnancy. P105 One (in press).
18. Ibanez A, Clotet B, and Martinez MA: Absence of genetic diversity reduction in the HIV-1 integrated proviral LTR sequence population during successful combination therapy. Virology 2001;282:1-5.
19. Tapia N, et al.: Influence of human immunodeficiency virus type 1 subtype on mother-to-child transmission. J Gen Virol 2003;84:607-613.
20. Thompson JD, Higgins DG, and Gibson TJ: CLUSTAL W: Improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res 1994;22:4673-4680.
21. Fernandez G, et al.: Purifying selection of CCR5-tropic HIV-1 variants in AIDS subjects that have developed syncytium-inducing CXCR4-tropic viruses. J Gen Virol 2006;87:1285-1294.
22. Fernandez G, et al.: Fitness landscape of HIV-1 protease quasispecies. J Virol 2007;81:2485-2496.
23. Swofford DL: PAUP*. Phylogenetic Analysis Using Parsimony (*and Other Methods). Version 4. Sinauer Associates, Sunderland, MA, 2003.
24. Akaike H: A new look at statistical model identification. IEEE Trans Automatic Control 1997;19:716-723.
25. Page RDM: TREEVIEW: An application to display phylogenetic trees on personal computers. Comput Appl Biosci 1996;12:357-358.
26. Aylor DL, Price EW, and Carbone I: SNAP: Combine and map modules for multilocus population genetic analysis. Bioinformatics 2006;22:1399-1401.
27. Price EW and Carbone I: SNAP: Workbench management tool for evolutionary population genetic analysis. Bioinformatics 2005;21:402-404.
28. Brumme ZL, et al.: Clinical and immunological impact of HIV envelope V3 sequence variation after starting initial triple antiretroviral therapy. AIDS 2004;18:F1-F9.
29. Jensen MA, Coetzer M, van't Wout AB, Morris L, and Mullins JI: A reliable phenotype predictor for human immunodeficiency virus type 1 subtype C based on envelope V3 sequences. J Virol 2006;80:4698-4704.
30. Jensen MA, et al.: Improved coreceptor usage prediction and genotypic monitoring of R5-to-X4 transition by motif analysis of HIV-1 env V3 loop sequences. J Virol 2003;77:13376-13388.
31. Xiao L, et al.: CCR5 coreceptor usage of non-syncytium-inducing primary HIV-1 is independent of phylogenetically distinct global HIV-1 isolates: Delineation of consensus motif in the V3 domain that predicts CCR-5 usage. Virology 1998;240:83-92.
32. Pollakis G, et al.: N-linked glycosylation of the HIV type-1 gp120 envelope glycoprotein as a major determinant of CCR5 and CXCR4 coreceptor utilization. J Biol Chem 2001;276:13433-13441.
33. Arroyo MA, et al.: HIV-1 diversity and prevalence differ between urban and rural areas in the Mbeya region of Tanzania. AIDS 2005;19:1517-1524.
34. Gordon M, et al.: Molecular characteristics of human immunodeficiency virus type 1 subtype C viruses from KwaZulu-Natal, South Africa: Implications for vaccine and antiretroviral control strategies. J Virol 2003;77:2587-2599.
35. Nhacolo AQ, et al.: Levels and trends of demographic indices in southern rural Mozambique: Evidence from demographic surveillance in Manhica district. BMC Public Health 2006;6:291.
36. Arien KK, Vanham G, and Arts EJ: Is HIV-1 evolving to a less virulent form in humans? Nat Rev Microbiol 2007;5:141-151.
37. Marechal V, et al.: Increasing HIV type 1 polymorphic diversity but no resistance to antiretroviral drugs in untreated patients from Central African Republic: A 2005 study. AIDS Res Hum Retroviruses 2006;22:1036-1044.
38. Perno CF, et al.: Low prevalence of primary mutations associated with drug resistance in antiviral-naive patients at therapy initiation. AIDS 2002;16:619-624.
39. Perno CF, et al.: Secondary mutations in the protease region of human immunodeficiency virus and virologic failure in drug-naive patients treated with protease inhibitor-based therapy. J Infect Dis 2001;184:983-991.
40. Connor RI, Sheridan KE, Ceradini D, Choe S, and Landau NR: Change in coreceptor use correlates with disease progression in HIV-1-infected individuals. J Exp Med 1997;185:621-628.
41. Pastore C, Ramos A, and Mosier DE: Intrinsic obstacles to human immunodeficiency virus type 1 coreceptor switching. J Virol 2004;78:7565-7574.
42. Johnston ER, et al.: High frequency of syncytium-inducing and CXCR4-tropic viruses among human immunodeficiency virus type 1 subtype C-infected patients receiving antiretroviral treatment. J Virol 2003;77:7682-7688.
43. Ping LH, et al.: Characterization of V3 sequence heterogeneity in subtype C human immunodeficiency virus type 1 isolates from Malawi: Underrepresentation of X4 variants. J Virol 1999;73:6271-6281.
44. Coetzer M, et al.: Longitudinal analysis of HIV type 1 subtype C envelope sequences from South Africa. AIDS Res Hum Retroviruses 2007;23:316-321.
45. Morris L, Cilliers T, Bredell H, Phoswa M, and Martin DJ: CCR5 is the major coreceptor used by HIV-1 subtype C isolates from patients with active tuberculosis. AIDS Res Hum Retroviruses 2001;17:697-701.
46. Peeters M, et al.: Evidence for differences in MT2 cell tropism according to genetic subtypes of HIV-1: Syncytium-inducing variants seem rare among subtype C HIV-1 viruses. J Acquir Immune Defic Syndr 1999;20:115-121.